4.1 Review

Sexual Dysfunction, Depression, and the Impact of Antidepressants

期刊

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
卷 29, 期 2, 页码 157-164

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JCP.0b013e31819c76e9

关键词

sexual dysfunction; SSRI; antidepressant; major depressive disorder; agomelatine

资金

  1. Institut de Recherches Internationales Servier
  2. Advanced Neuromodulation Systems Inc
  3. AstraZeneca
  4. Biovail
  5. Boehringer-Ingelhem
  6. Eli Lilly
  7. GlaxoSmithKline
  8. Janssen-Ortho
  9. Lundbeck
  10. Merck Frost
  11. Wyeth

向作者/读者索取更多资源

Sexual dysfunction is a common symptom of depression. Although decreased libido is most often reported, difficulties with arousal, resulting in vaginal dryness in women and erectile dysfunction in men, and absent or delayed orgasm are also prevalent. Sexual dysfunction is also a frequent adverse effect of treatment with most antidepressants and is one of the predominant reasons for premature drug discontinuation. Selective serotonin reuptake inhibitors are the most widely prescribed anti depressants and have significant effects on arousal and orgasm compared with antidepressants that target norepinephrine, dopamine, and melatonin systems. The availability of an antidepressant that does not cause or exacerbate sexual dysfunction represents an advance in pharmacotherapy for mood disorders and should reduce treatment noncompliance and decrease the need for switching antidepressants or adding antidotes. The purpose of this review was to provide an update on the prevalence, psychobiology, and relative adverse effect burden of sexual dysfunction associated with different antidepressants.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据